Submitted by Anonymous (not verified) on 16 July 2025 - 16:05
Human medicines European public assessment report (EPAR): Crysvita, burosumab, Date of authorisation: 19/02/2018, Revision: 15, Status: Authorised
Source:
Human medicines European public assessment report (EPAR): Crysvita, burosumab, Date of authorisation: 19/02/2018, Revision: 15, Status: Authorised